Veru Inc. (VERU) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Veru Inc. (VERU) trades at $2.58 with AI Score 28/100 (Grade F). Veru Inc. is an oncology biopharmaceutical company focused on developing medicines for managing cancers and other diseases. Market cap: $41.4M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for VERU: VERU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VERU against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VERU: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Veru Inc. (VERU) Healthcare & Pipeline Overview
Veru Inc. is a biopharmaceutical company specializing in oncology, focusing on developing novel treatments for various cancers and infectious diseases. The company's portfolio includes the FC2 female condom and a pipeline of clinical-stage drug candidates, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for VERU?
Veru Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's pipeline of oncology drug candidates, particularly Enobosarm and Sabizabulin, represents significant potential value drivers if clinical trials are successful and regulatory approvals are obtained. The current market capitalization of $41.4M may undervalue the potential of these assets, especially considering the unmet medical needs in the targeted cancer indications. However, the company's negative profit margin of -7736.3% and gross margin of -46.7% highlight substantial financial challenges. The negative beta of -1.34 suggests the stock moves inversely to the market, potentially offering diversification benefits but also indicating sensitivity to company-specific risks. Upcoming clinical trial results and regulatory decisions will be critical catalysts for Veru's stock performance. Investors should carefully weigh the potential upside against the significant risks associated with biotechnology investments, including clinical trial failures, regulatory hurdles, and financial constraints.
Based on FMP financials and quantitative analysis
VERU Key Highlights
Market Cap of $41.4M reflects the company's small size and potential for high growth or significant risk.
- Profit Margin of -7736.3% indicates substantial losses and the need for successful drug development and commercialization.
- Gross Margin of -46.7% suggests challenges in cost management and pricing strategies for its commercial product, FC2.
- Beta of -1.34 implies the stock has historically moved inversely to the market, offering potential diversification benefits.
- Focus on oncology with multiple drug candidates in clinical trials positions Veru in a high-growth but also high-risk sector.
Who Are VERU's Competitors?
VERU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| AMGN Amgen Inc. | $433.73 | -1.95% | $234B | 86 |
| PFE Pfizer Inc. | $27.82 | -1.50% | $159B | 67 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 78 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VERU's Key Strengths?
Pipeline of drug candidates targeting unmet needs in oncology.
- Commercial product (FC2) generating revenue.
- Experienced management team.
- Focus on specific therapeutic areas.
What Are VERU's Weaknesses?
Negative profit and gross margins.
- Reliance on successful clinical trial outcomes.
- Limited financial resources compared to larger competitors.
- High R&D expenses.
What Could Drive VERU Stock Higher?
VERU catalyst: Results from Phase III clinical trial of Enobosarm for AR+ ER+ HER2- metastatic breast cancer.
- Results from Phase IIb clinical trial of Sabizabulin for AR+ ER+ HER2- metastatic breast cancer.
- Regulatory decisions regarding potential approval of Enobosarm or Sabizabulin.
- Progress in clinical trials for VERU-100 in advanced hormone-sensitive prostate cancer.
- Development of new drug formulations for lower urinary tract symptoms.
What Are the Key Risks for VERU?
Financial-distress signal — its Altman Z-Score of -11.41 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-45.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials for key drug candidates.
- Delays or rejection of regulatory approvals.
- Competition from larger pharmaceutical companies.
- Dependence on limited financial resources.
- Changes in healthcare policies affecting drug pricing and reimbursement.
What Are the Growth Opportunities for VERU?
- Enobosarm for AR+ ER+ HER2- Metastatic Breast Cancer: Enobosarm, an oral selective androgen receptor agonist, is in Phase III clinical trials for the treatment of AR+ ER+ HER2- metastatic breast cancer. Successful completion of Phase III trials and subsequent regulatory approval could provide Veru with a significant revenue stream. The ongoing clinical trials are expected to conclude in the near term, potentially leading to a new treatment option for patients with this specific type of breast cancer.
- Sabizabulin for AR+ ER+ HER2- Metastatic Breast Cancer: Sabizabulin, currently in Phase IIb clinical trials, targets AR+ ER+ HER2- metastatic breast cancer. This drug offers a different mechanism of action, potentially providing an alternative treatment option for patients who have not responded to other therapies. The successful development of Sabizabulin could expand Veru's oncology portfolio and increase its market presence. The Phase IIb trial results will be a key milestone in determining the drug's future prospects.
- Enobosarm + Abemaciclib Combination Therapy: Veru is exploring the combination of Enobosarm with abemaciclib in Phase III clinical trials for AR+ ER+ HER2- metastatic breast cancer. Combination therapies are increasingly important in cancer treatment, offering the potential for synergistic effects and improved patient outcomes. If successful, this combination therapy could become a new standard of care. The results from the Phase III trial will be crucial in assessing the efficacy and safety of this approach.
- Sabizabulin for Metastatic Castration and Androgen Receptor Targeting Agent Resistant Prostate Cancer: Sabizabulin is also being investigated in Phase II clinical trials for the treatment of metastatic castration and androgen receptor targeting agent-resistant prostate cancer. Prostate cancer is a significant market, and there is a need for new treatments that can overcome resistance to existing therapies. Positive results from the Phase II trial could lead to further development and commercialization opportunities.
- Sabizabulin for SARS-CoV-2: Sabizabulin is in Phase III clinical trials for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. While the pandemic has subsided, there remains a need for effective treatments for high-risk individuals. If Sabizabulin proves effective, it could provide a valuable tool in managing future outbreaks and reducing the severity of COVID-19 infections. The results of the Phase III trial will determine the drug's potential in this indication.
What Opportunities Does VERU Have?
- Successful clinical trial results leading to regulatory approvals.
- Partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Increased demand for targeted cancer therapies.
What Are VERU's Competitive Advantages?
- Proprietary drug candidates in clinical development.
- Established distribution network for FC2 female condoms.
- Intellectual property protection for its drug candidates.
- Expertise in oncology drug development and commercialization.
What Does VERU Do?
Veru Inc., formerly known as The Female Health Company, was incorporated in 1971 and rebranded in July 2017 to reflect its expanded focus on oncology. Headquartered in Miami, Florida, the company is dedicated to developing and commercializing medicines for the management of cancers. Veru's commercial product, FC2 female condom/internal condom, provides dual protection against unintended pregnancy and sexually transmitted infections, targeting ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company’s development pipeline includes several drug candidates in various stages of clinical trials. Key candidates include Enobosarm, an oral selective androgen receptor agonist in Phase III trials for AR+ ER+ HER2- metastatic breast cancer, and Sabizabulin, in Phase IIb trials for the same indication. Veru is also exploring combination therapies, such as Enobosarm + abemaciclib and Sabizabulin + enobosarm, to address metastatic triple-negative breast cancer. Additionally, Veru is developing Sabizabulin for metastatic castration and androgen receptor targeting agent-resistant prostate cancer, VERU-100 for advanced hormone-sensitive prostate cancer, and Zuclomiphene Citrate for treating hot flashes. The company is also investigating Sabizabulin for treating SARS-CoV-2 in high-risk subjects. Veru is also advancing a new drug formulation for lower urinary tract symptoms in men with enlarged prostates.
What Products and Services Does VERU Offer?
- Develop medicines for the management of cancers.
- Commercialize FC2 female condom for protection against unintended pregnancy and STIs.
- Conduct Phase III clinical trials for Enobosarm in metastatic breast cancer.
- Conduct Phase IIb clinical trials for Sabizabulin in metastatic breast cancer.
- Develop combination therapies for metastatic breast cancer.
- Investigate Sabizabulin for prostate cancer treatment.
- Develop VERU-100 for advanced hormone-sensitive prostate cancer.
- Research Zuclomiphene Citrate for treating hot flashes.
How Does VERU Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of FC2 female condoms.
- Out-license or partner with other companies for drug development and commercialization.
- Focus on oncology and infectious diseases to address unmet medical needs.
What Industry Does VERU Operate In?
Veru Inc. operates within the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and significant investment in research and development. The oncology segment, in particular, is a major area of focus, driven by the increasing prevalence of cancer and the demand for more effective treatments. Veru's pipeline of drug candidates targets specific unmet needs in breast cancer and prostate cancer, positioning it to potentially capture market share if its clinical trials are successful. The company competes with both large pharmaceutical companies and smaller biotech firms, requiring a focused strategy and efficient execution to succeed. Market trends include the growing importance of personalized medicine, combination therapies, and targeted treatments.
Who Are VERU's Key Customers?
- Ministries of health and government health agencies.
- U.N. agencies and nonprofit organizations.
- Commercial partners for FC2 distribution.
- Patients with cancer and other diseases.
- Healthcare providers and hospitals.
Forward Outlook
Wall Street analysts project Veru Inc. revenue of about $2.7M for fiscal 2026, with EPS near $-1.01. The estimate reflects 3 contributing analysts.
Financial Health
Veru Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.41 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Veru Inc. stands at -45.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -63.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.1%, the inverse of the P/E and a quick read on earnings relative to price.
Veru Inc. (VERU) Valuation Context
Valued at $41.4M, VERU is classified as a micro-cap stock. Relative to its peer group, VERU's quantitative score of 28/100 is below the peer average of 75/100.
Company Profile
Veru Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Mitchell S. Steiner. VERU has traded publicly since 1999.
VERU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Veru's future prospects, indicating that those closest to the company believe in its potential growth.
- Community sentiment has turned positive as recent developments in clinical trials have shown promising results, leading to increased optimism among investors.
- Analysts have noted the strategic partnerships Veru is forming, which could enhance its market reach and product development capabilities.
- The overall healthcare sector has seen a resurgence in interest, and Veru's innovative pipeline aligns well with current market trends favoring biotech advancements.
Bear Case
- Despite positive sentiment, some investors remain cautious due to the inherent volatility in biotech stocks, which can lead to unpredictable price swings.
- There has been criticism regarding the pace of product development, with some questioning whether Veru can keep up with competitors in the rapidly evolving market.
- Recent market chatter indicates concerns about regulatory hurdles that could delay product launches, potentially impacting future revenue streams.
- Some community members express skepticism about the sustainability of Veru's recent gains, fearing a pullback if upcoming earnings do not meet heightened expectations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VERU Latest News
-
Earnings Scheduled For February 11, 2026
benzinga · Feb 11, 2026
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Mar 20, 2023
-
Stocks That Hit 52-Week Highs On Monday
· Dec 23, 2019
-
Stocks That Hit 52-Week Highs On Tuesday
· Dec 16, 2019
VERU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VERU.
Price Targets
Wall Street price target analysis for VERU.
VERU MoonshotScore
What does this score mean?
The MoonshotScore rates VERU 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Mitchell S. Steiner
Chief Executive Officer
Mitchell S. Steiner has served as the Chief Executive Officer of Veru Inc. He brings extensive experience in the pharmaceutical and biotechnology industries, with a background in drug development, clinical research, and commercialization. His career includes leadership roles in various healthcare companies, focusing on oncology and related therapeutic areas. Steiner's expertise spans from early-stage research to late-stage clinical trials and market launch, making him well-suited to guide Veru through its current development pipeline.
Track Record: Under Mitchell S. Steiner's leadership, Veru Inc. has focused on advancing its oncology pipeline, particularly Enobosarm and Sabizabulin, through clinical trials. He has overseen the company's strategic shift towards oncology and the development of combination therapies. Key milestones include the progression of Enobosarm into Phase III trials and the initiation of studies for Sabizabulin in various cancer indications. Steiner has also managed the commercialization of FC2 and navigated the challenges of operating a small biotechnology company.
VERU Healthcare Stock FAQ
What does the AI Score mean for VERU?
VERU holds an AI Score of 28/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Veru Inc. is an oncology biopharmaceutical company focused on developing medicines for managing cancers and other diseases. Its portfolio includes both commercial products like FC2 and a pipeline …
What does Veru Inc. do?
Veru Inc. is an oncology biopharmaceutical company focused on developing and commercializing novel medicines for the management of cancers. The company's portfolio includes the FC2 female condom, which provides protection against unintended pregnancy and sexually transmitted infections, and a pipeline of clinical-stage drug candidates targeting various cancers, including breast cancer and prostate cancer.
What do analysts say about VERU stock?
Analyst coverage of Veru Inc. is limited, reflecting its small market capitalization and early-stage development pipeline. The consensus view typically focuses on the potential of its key drug candidates, particularly Enobosarm and Sabizabulin, and the associated risks of clinical trial failures and regulatory hurdles.
What are the main risks for VERU?
Veru Inc. faces several key risks inherent to the biotechnology industry. Clinical trial risk is paramount, as the failure of Enobosarm or Sabizabulin to demonstrate efficacy or safety in Phase III trials would significantly impact the company's value.
What revenue streams does Veru Inc. have in healthcare?
Veru Inc.'s primary revenue stream in healthcare currently comes from the sales of FC2 female condoms. While the company is focused on oncology drug development, FC2 provides a consistent, albeit modest, revenue source. The company anticipates future revenue streams from its oncology pipeline, specifically Enobosarm and Sabizabulin, if clinical trials are successful and regulatory approvals are obtained.
How does Veru Inc. navigate regulatory approval processes?
Veru Inc. navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its drug candidates. The company works closely with regulatory agencies, such as the FDA, to ensure compliance with all applicable regulations and guidelines.
What are the key factors to evaluate for VERU?
Veru Inc. (VERU) holds an AI score of 28/100 (low). presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does VERU data refresh on this page?
VERU's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VERU's recent stock price performance?
Veru Inc. (VERU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Pipeline of drug candidates targeting unmet needs in oncology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment in biotechnology companies is inherently risky and speculative.